Powerful AI models for biology exist, but the industry lacks a breakthrough user interface—a "ChatGPT for science"—that makes them accessible, trustworthy, and integrated into wet lab scientists' workflows. This adoption and translation problem is the biggest hurdle, not the raw capability of the AI models themselves.

The integration of AI in drug development has been extraordinarily fast. What were vague, 'hand wavy' AI/ML claims on pitch decks just 3-4 years ago have, since ChatGPT's 2022 arrival, become a fundamental, end-to-end retooling of how the industry discovers and develops drugs.

Beyond productivity gains, AI's most transformative impact may be automating R&D to accelerate scientific discovery. This could lead to breakthroughs in health and wellness, solving problems that might otherwise take decades and fundamentally improving quality of life, not just GDP.

AI's true power in science isn't autonomous discovery, but process compression. It acts as an expert guide, allowing motivated individuals to navigate complex fields like drug discovery and assemble workflows that once required multiple specialized teams, blurring the line between professional research and individual effort.

The "AI vs. Dog Cancer" story shows that current AI's power is not autonomous discovery, but its ability to act as a research assistant, enabling motivated non-experts to orchestrate complex scientific projects by finding and coordinating with human experts.

AI is reducing the cognitive overhead required to navigate biological knowledge, blurring the line between professional labs and motivated individuals. This trend actualizes Freeman Dyson's 2007 prediction that biotech, like computing, would become a decentralized, creative craft.

While many focus on AI's business applications, its most profound benefit will be in science. Leaders like Google's Demis Hassabis believe AI will solve humanity's hardest problems in math, physics, and biology, with the potential to cure all diseases within a decade.

The combination of AI's reasoning ability and cloud-accessible autonomous labs will remove the physical barriers to scientific experimentation. Just as AWS enabled millions to become programmers without owning servers, this new paradigm will empower millions of 'citizen scientists' to pursue their own research ideas.

A major biotech revolution is underway as AI now enables effective 'in silico' (simulated) experiments. This shift from physical "wet labs" to cheap, infinitely scalable simulations drastically cuts time and cost for drug discovery, making audacious goals like curing cancer scientifically plausible.